BIONTECH SE SPON. ADRS 1
Commented by Juliane Zielonka on May 10th, 2022 | 12:38 CEST
Biotech stocks: Defence Therapeutics, BioNTech, BASF - Advantage through platform technology
Large corporations such as BASF were previously considered safe portfolio investments. But the war in Ukraine is throwing a spanner in the works. Force majeure, such as war, can cause deals to fall through without the responsibility of the companies involved. How should investors react now? Which portfolio strategy can keep up with the high volatility of the markets? Newcomers like BioNTech face oversupply and have to accept shortages. A focus on emerging markets seems to be the solution for their growth strategy. But there are subtle differences in the vaccines business, as Defence Therapeutics proves.
Read
Commented by Nico Popp on May 5th, 2022 | 11:52 CEST
Biotech-Investments also work conservatively: BioNTech, XPhyto, Valneva
Biotech stocks are often seen as all-or-nothing investments - either a bet works out, or the companies disappear into oblivion. But innovative companies in the pharmaceutical and biotech sectors do not always operate in just one area. They are not always spectacular projects that are dependent on approval procedures. We outline the investment opportunities around three well-known biotech stocks.
Read
Commented by Fabian Lorenz on May 3rd, 2022 | 11:48 CEST
BYD and Altech with strong news: Hope for BioNTech shares?
Rising interest rates, the war in Ukraine, lockdowns in China and recession fears: the current global mix is not conducive to rising share prices, but there is also positive news from companies. Among them is BYD. The largest Chinese manufacturer of electric cars has published quarterly figures and thus convinced analysts. In addition, BYD is celebrating the delivery anniversary of its flagship. The share of Altech Advanced Materials is also currently stepping on the gas. A study has confirmed that the planned production plant of the Heidelberg-based Company can be highly profitable. With the plant, Altech wants to stir up the market for lithium-ion batteries. BioNTech shareholders are still waiting for positive news - but there is hope.
Read
Commented by André Will-Laudien on May 2nd, 2022 | 13:27 CEST
BioNTech, Defence Therapeutics, Valneva, MorphoSys - Biotech stocks that will still be fun tomorrow!
One of the most churned areas on the growth stock market is the biotech sector. There was too much disappointment on the drug development side; even in the COVID sector, only a few winners remain. However, the current sell-off could turn out to be an entry opportunity in the medium term because there are more and more people on earth and, fortunately, they are getting older and older; even the Corona pandemic is not likely to change this. There are already 1 billion people worldwide over the age of 60, and forecasts predict that this figure will rise to 2 billion by 2050 - with a total population of more than 9 billion people predicted at that time. Which values have been unjustly neglected, and where are the current opportunities for investors?
Read
Commented by Stefan Feulner on April 29th, 2022 | 11:16 CEST
BioNTech, NervGen, Sanofi - The rebound is on the way
Uncertainties remain. Admittedly, infection figures are falling in the Corona pandemic and should ensure a quiet summer in this respect. In addition to inflation remaining at a high level, the Ukraine conflict moved to the front news pages. It has caused panic and strong sales on the stock markets in recent weeks. After the DAX marked another interim low at around 13,500 points yesterday, the stock market barometer turned around but is struggling with the psychologically important mark at 14,000 points. Now the quarterly season has begun, which could provide positive impetus. Commerzbank and Deutsche Bank started it off and were quite convincing.
Read
Commented by Fabian Lorenz on April 28th, 2022 | 13:00 CEST
BioNTech share price about to double? Varta and Meta Materials with newsflow, or not
Those who are currently betting on rising prices on the stock market need strong nerves. But some companies are worth a closer look. Among others, this applies to BioNTech. The Company is facing important deadlines, continues to earn billions with its Corona vaccine and has an attractive product pipeline. The analysts at Berenberg, for example, see doubling potential after the stock has bottomed out. Meta Materials has also formed a bottom formation, and at the same time, there was positive newsflow from the developer of revolutionary products. Varta shareholders have been hoping for this for some time, but in vain. The share is battered, and even the current financial injection cannot change that.
Read
Commented by Nico Popp on April 27th, 2022 | 11:54 CEST
Where the sentiment is right: BioNTech, Defence Therapeutics, Amazon
If you want to sell air mattresses in November, you will not succeed even with huge discounts. It is a similar story when selecting stocks. In order to reap returns, investors need to assess the market and bet on the stocks that will be in demand in the near future. In the case of vaccine stocks, the air seemed to be out recently. But now, there are growing indications that more vaccine doses may be needed. We take a look at the sentiment of three stocks.
Read
Commented by Nico Popp on April 20th, 2022 | 12:04 CEST
Where the music is playing now: BioNTech, MAS Gold, Bayer
Capitalism is the best system when it comes to distributing goods effectively. Supply and demand first make scarce goods expensive and then turn them into a promising business area. That is what happened with vaccines. Today, the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) is warning of an oversupply of Corona vaccines - two years ago, things looked very different. While biotech stocks such as BioNTech are being penalized, it is important to identify tomorrow's opportunities. Scarcity plays an important role here.
Read
Commented by André Will-Laudien on April 19th, 2022 | 10:49 CEST
Watch out: BioNTech, NervGen, Valneva, CureVac: The next waves of biotech stocks are rolling!
The start of spring - and where to now? The mild flu outbreaks due to the Omicron variant and associated massive relaxations of Corona measures in many countries are weighing on the prospects of vaccine manufacturers in the short term. After all, there are no clinical bottlenecks, and the vaccination rate does not want to increase despite massive public campaigns. Mandatory vaccination is also off the table, and for the biotech industry and vaccine producers, this results in a need to keep researching other topics! Many diseases are more dangerous for us humans than Corona. We look at important protagonists.
Read
Commented by Stefan Feulner on April 12th, 2022 | 20:31 CEST
BioNTech, Desert Gold Ventures, BYD - Decisive steps
There is currently great uncertainty on the capital markets. While the Ukraine war and the fear of interest rate hikes due to the enormous increase in inflation are weighing on the minds of investors in Europe, investors in Asia are pulling back due to the tightened Corona measures in China. The zero-covid policy could result in widespread mass shutdowns, negatively impacting industrial production and domestic consumption. Electric car maker NIO, for example, has already halted production.
Read